Compare Trip.com Group Ltd (TCOM) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Trip.com Group Ltd vs State Street SPDR S&P Biotech ETF — how do they compare? Trip.com Group Ltd trades at $46.2 (market cap $29.10B), while State Street SPDR S&P Biotech ETF trades at $159.35. The key difference: Trip.com Group Ltd pays a 0.42% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Trip.com Group Ltd nearer its low. Which is the better fit depends on your goals.
| TCOM | XBI | |
|---|---|---|
Market Cap | $29.10B | — |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $78.96 | $164.28 |
52-Week Low | $39.84 | $86.92 |
Enterprise Value | $21.75B | — |
Dividend Yield | 0.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Trip.com (TCOM) trades at $45.62, down 3.19% amid bearish technical signals despite strong fundamentals. The company reported robust 2025 results with $62.41B revenue and 53.34% net margin, though recent quarters show mixed earnings performance. Regulatory headwinds persist with a $770M antitrust penalty from China's market regulator in July 2026, while analyst consensus remains bullish with a $59.29 price target.
The stock faces near-term pressure from regulatory scrutiny and technical weakness, but attractive valuations (P/E 6.89) and dominant market position offer long-term upside if execution improves. Key risks include China's regulatory environment and competitive pressures, while institutional ownership shifts indicate cautious sentiment despite Wall Street's buy ratings.
XBI trades at $158.81, up 0.49% today, with a bullish technical signal supported by moving averages. The ETF shows strong momentum with a 17% monthly gain and 75% annual return, driven by biotech sector strength. Analyst coverage is limited to one hold rating, while recent news highlights institutional buying interest and positive sector developments including M&A activity and drug trial successes.
The outlook remains positive given biotech's breakout from multi-year bear markets, though elevated volatility and policy risks persist. Key opportunities include AI-driven drug discovery and sustained M&A momentum, while risks involve sector-specific volatility and regulatory uncertainty. The ETF's equal-weight approach provides diversified exposure to biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Trip.com Group Ltd
Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 78% of sales from accommodation reservations and transportation ticketing in 2020. The rest of revenue comes from package tours and corporate travel. Prior to the pandemic in 2019, the company generated 25% of revenue from international business, which is important to its margin expansion. Most of sales come from websites and mobile platforms, while the rest come from call centers. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Toncheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.
Read more on TCOM →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
